Assessment of patients with idiopathic inflammatory myopathies and isolated creatin-kinase elevation

Iaccarino L, Ghirardello A, Bettio S, Zen M, Gatto M, Punzi L, Doria A (2014) The clinical features, diagnosis and classification of dermatomyositis. J Autoimmun 48–49:122–127

Briani C, Doria A, Sarzi-Puttini P, Dalakas MC (2006) Update on idiopathic inflammatory myopathies. Autoimmunity 39:161–170

Iaccarino L, Gatto M, Bettio S, Caso F, Rampudda M, Zen M, Ghirardello A, Punzi L, Doria A (2013) Overlap connective tissue disease syndromes. Autoimmun Rev 12:363–373

Hervier B, Devilliers H, Stanciu R et al (2012) Hierarchical cluster and survival analyses of antisynthetase syndrome: phenotype and outcome are correlated with anti-tRNA synthetase antibody specificity. Autoimmun Rev 12:2010–2017

Dalakas MC, Hohlfeld R (2003) Polymyositis and dermatomyositis. Lancet 362:971–982

Yuan L, Yao L, Zhao L, Xia L, Shen H, Lu J (2013) Serum levels of soluble ST2 and interleukin-33 in patients with dermatomyositis and polymyositis. Clin Exp Rheumatol 31:428–432

Ghirardello A, Bassi N, Palma L, Borella E, Domeneghetti M, Punzi L, Doria A (2013) Autoantibodies in polymyositis and dermatomyositis. Curr Rheumatol Rep 15:335

Hengstman GJ, ter Laak HJ, Vree Egberts WT, Lundberg IE, Moutsopoulos HM, Vencovsky J, Doria A, Mosca M, van Venrooij WJ, van Engelen BG (2006) Anti-signal recognition particle autoantibodies: marker of a necrotizing myopathy. Ann Rheum Dis 65:1635–1638

Ghirardello A, Zampieri S, Iaccarino L, Tarricone E, Bendo R, Gambari PF, Doria A (2005) anti-Mi-2 antibodies. Autoimmunity 38:79–83

Zampieri S, Ghirardello A, Iaccarino L, Tarricone E, Gambari PF, Doria A (2005) Anti-Jo-1 antibodies. Autoimmunity 38:73–78

Oddis CV, Rider LG, Reed AM et al (2005) International consensus guidelines for trials of therapies in idiopathic inflammatory myopathies. Arthritis Rheum 52:2607–2615

Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (first part). N Engl J Med 292:344–347

Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (second part). N Engl J Med 292:403–407

Linklater H, Pipitone N, Rose MR, Norwood F, Campbell R, Salvarani C, Scott DL, Gordon P (2013) Classifying idiopathic inflammatory myopathies: comparing the performance of six existing criteria. Clin Exp Rheumatol 31:767–769

Targoff IN, Miller FW, Medsger TA, Oddis CV (1997) Classification criteria for idiopathic inflammatory myopathies. Curr Opin Rheumatol 9:527–535

Troyanov Y, Targoff IN, Tremblay JL, Goulet JR, Raymond Y, Senecal JL (2005) Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients. Medicine 84:231–249

Miller FW, Rider LG, Plotz PH, Isenberg DA, Oddis CV (2003) Diagnostic criteria for polymyositis and dermatomyositis. Lancet 362:1762–1763

Hoogendijk JE, Amato AA, Lecky BR et al (2004) 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10–12 october 2003, Naarden, The Netherlands. Neuromuscul Disord 14:337–345

Miller FW, Rider LG, Chung YL et al (2001) Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies. Rheumatology 40:1262–1273

Rider LG, Werth VP, Huber AM, Alexanderson H, Rao AP, Ruperto N, Herbelin L, Barohn R, Isenberg D, Miller FW (2011) Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis. Arthritis Care Res 63:S118–S157

Rider LG, Giannini EH, Harris-Love M et al (2003) Defining clinical improvement in adult and juvenile myositis. J Rheumatol 30:603–617

Rider LG, Koziol D, Giannini EH et al (2010) Validation of manual muscle testing and a subset of eight muscles for adult and juvenile idiopathic inflammatory myopathies. Arthritis Care Res 62:465–472

Hay EM, Bacon PA, Gordon C, Isenberg DA, Maddison P, Snaith ML, Symmons DP, Viner N, Zoma A (1993) The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q J Med 86:447–458

Brewster LM, Mairuhu G, Sturk A, van Montfrans GA (2007) Distribution of creatine kinase in the general population: implications for statin therapy. Am Heart J 154:655–661

Prelle A, Tancredi L, Sciacco M et al (2002) Retrospective study of a large population of patients with asymptomatic or minimally symptomatic raised plasmacreatine kinase levels. J Neurol 249:305–311

Simmons Z, Peterlin BL, Boyer PJ, Towfighi J (2003) Muscle biopsy in the evaluation of patients with modestly elevated creatine kinase levels. Muscle Nerve 27:242–244

Rowland LP, Willner J, DiMauro S, Miranda A (1980) Approaches to the membrane theory of Duchenne muscular dystrophy. In: Angelini C, Danieli GA, Fontanari D (eds) Muscular dystrophy-advances and new trends. Excerpta Medica, Amsterdam, pp 3–13

Vaughan CJ, Gotto AM Jr (2004) Update on statins: 2003. Circulation 17(110):886–892

Kyriakides T, Angelini C, Schaefer J et al (2010) EFNS guidelines on the diagnostic approach to pauci- or asymptomatic hyperCKemia. Eur J Neurol 17:767–773

Rossi D, Vezzani B, Galli L et al (2014) A mutation in the CASQ1 GeneCauses a vacuolar myopathy with accumulation of sarcoplasmic reticulum proteinAggregates. Hum Mutat. doi: 10.1002/humu.22631

Fanin M, Nascimbeni AC, Aurino S, Tasca E, Pegoraro E, Nigro V, Angelini C (2009) Frequency of LGMD gene mutations in Italian patients with distinct clinical phenotypes. Neurology 21(72):1432–1435

Morandi L, Angelini C, Prelle A, Pini A, Grassi B, Bernardi G, Politano L, Bruno C, De Grandis D, Cudia P, Citterio A (2006) High plasma creatine kinase: review of the literature and proposal for a diagnostic algorithm. Neurol Sci 27:303–311